ArticleJournal of veterinary internal medicine2026
Thymidine kinase 1 activity in serum and body cavity fluids of horses with lymphoma.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe accuracy of serum thymidine kinase 1 (TK1S) as a biomarker of lymphoma in horses is variable. The value of measurement in body cavity fluid (TK1F) has not been established. HYPOTHESIS/
objectives(1) TK1F and TK1S will be higher in horses with lymphoma compared to diseased controls (DCs); (2) TK1F will be higher than TK1S; and (3) there will be a strong correlation between both measurements. ANIMALS: Twenty animals in the lymphoma and 31 animals with nonneoplastic, gastrointestinal/respiratory disorders in DC group.
methodsThis was a cross-sectional study using prospectively collected data and samples obtained during routine diagnostic evaluation at referral hospitals. Thymidine kinase 1 was measured using chemiluminescence immunoassay and presented as median (and interquartile range). Nonparametric tests compared TK1F and TK1S between and within groups and Kendall's Tau assessed correlation between TK1F and TK1S.
resultsMedian TK1F was 7.48 (2.20-48.23) U/L in horses with lymphoma vs 2.50 (0.59-4.83) U/L in the DC group (P = .007); median TK1S was 4.26 (0.46-9.37) U/L vs 0.40 (0.40-0.75) U/L (P < .001), respectively. Both biomarkers showed good discrimination (area under the curve > 0.70) between lymphoma and the DC group, with optimal cutoff values of 5.7 and 2.5 U/L, respectively. Thymidine kinase 1 activity in body cavity fluid (3.62 [0.85-9.86] U/L) was significantly higher than TK1S (0.50 [0.40-2.09] U/L; P < .001) and there was no significant correlation between them within groups. CONCLUSIONS AND CLINICAL IMPORTANCE: Thymidine kinase 1 activity in body cavity fluid and TK1S provide different information and should be interpreted independently. They proved useful in lymphoma diagnosis, but not as a standalone test. ABSTRACT TRANSLATED TO GERMAN:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.